Critically ill patients with Covid-19 who have been treated with an arthritis drug that reduces inflammation are significantly more likely to have improved outcomes, according to early data from the REMAP-CAP trial. Led by Professor Anthony Gordon, Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust, the research evaluated the effect of the treatment on survival rates and the length of time patients need support in an intensive care unit (ICU).

 

 

Credit: iStock, South_agency

Read more…